Chronic Kidney Disease Trial, Recruiting NCT06556407 Sponsor: University of Erlangen-Nürnberg Medical School Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT06556407
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have high blood pressure that remains uncontrolled despite taking three different types of blood pressure medications, confirmed by a 24-hour blood pressure monitoring test showing readings above the thresholds set by current guidelines.
  • People who have end-stage kidney disease and are receiving regular dialysis (hemodialysis) to manage their condition.
  • People who have been on a stable dialysis schedule for at least 3 months, as determined by their treating doctor.
  • People who have been taking the same medications without any changes for at least 4 weeks.
  • People who are 18 years of age or older; both men and women are included.

Who may not be able to join:

  • People who have episodes of low blood pressure (shown by 24-hour monitoring or dialysis records) that their doctor believes would make the procedure unsafe.
  • People who have a known significant blockage or structural problem in the arteries leading to their kidneys that could make it unsafe to insert the required medical catheter.
  • People who have previously had a renal denervation procedure (a treatment targeting the nerves around the kidney arteries).
  • People who have only one functioning kidney, or who have received a kidney transplant.
  • People who have severe artery hardening or calcium build-up that would prevent reliable blood pressure readings being obtained.
  • People whose high blood pressure is caused by a hormonal condition, other than sleep apnea.
  • People who have had a heart attack, severe chest pain (unstable angina), or stroke within the 3 months before the study screening visit.
  • People who have had a recent flare-up of a systemic or kidney disease requiring an increase in immune-suppressing medication within the last 3 months.
  • People who are pregnant, breastfeeding, or planning to become pregnant.
  • People who are already enrolled in another interventional research study.
  • People who have any other condition that, in the opinion of the study investigator, would prevent safe or reliable participation in the trial (for example, difficulty following medical instructions).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +49 9131 8536207

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Erlangen-Nürnberg Medical School
Registry
ClinicalTrials.gov
Start date
4 March 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Safety endpoints and adverse effects; Change in 24-h ambulatory systolic blood pressure between baseline and 3 months post-procedure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov